{"id":"clobetasol-propionate-foam","safety":{"commonSideEffects":[{"rate":null,"effect":"Skin atrophy"},{"rate":null,"effect":"Telangiectasia"},{"rate":null,"effect":"Striae"},{"rate":null,"effect":"Folliculitis"},{"rate":null,"effect":"Hypertrichosis"},{"rate":null,"effect":"Acneiform eruptions"},{"rate":null,"effect":"Hypopigmentation"}]},"_chembl":{"chemblId":"CHEMBL1159650","moleculeType":"Small molecule","molecularWeight":"466.98"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Clobetasol propionate is a Class I (super-potent) corticosteroid that works by activating intracellular glucocorticoid receptors, leading to decreased production of inflammatory mediators, reduced immune cell infiltration, and suppression of local inflammatory responses. The foam formulation provides enhanced penetration and coverage for scalp and other affected areas. It is used to rapidly reduce inflammation, itching, and other dermatological symptoms in various skin conditions.","oneSentence":"Clobetasol propionate is a potent topical corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:31:48.405Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (scalp and body)"},{"name":"Psoriasis"},{"name":"Lichen planus"},{"name":"Atopic dermatitis"}]},"trialDetails":[{"nctId":"NCT04207931","phase":"PHASE4","title":"Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2018-04-30","conditions":"Central Centrifugal Cicatricial Alopecia (CCCA)","enrollment":250},{"nctId":"NCT00436540","phase":"PHASE4","title":"A Comparison Between Clobetasol Propionate 0.05% (Clobex®) Spray and Clobetasol Propionate 0.05% (Olux®) Foam","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2006-03","conditions":"Psoriasis","enrollment":78},{"nctId":"NCT00803439","phase":"","title":"Randomized Study to Compare the Bioavailability of Two Clobetasol Propionate 0.05% Topical Foams","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2005-04","conditions":"Healthy","enrollment":80},{"nctId":"NCT00438399","phase":"PHASE3","title":"Subject Preference for Scalp Psoriasis Treatment","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2007-02","conditions":"Scalp Psoriasis","enrollment":219},{"nctId":"NCT01591785","phase":"NA","title":"Treatment of Staphylococcus Aureus Colonization in Hand Eczema","status":"COMPLETED","sponsor":"Gary Goldenberg","startDate":"2012-01","conditions":"Hand Eczema, Foot Eczema","enrollment":60},{"nctId":"NCT03584360","phase":"PHASE2","title":"Role of Topical Treatments in the Modulation of Skin Microbiome in Psoriatic Skin","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2018-09-24","conditions":"Psoriasis Vulgaris","enrollment":30},{"nctId":"NCT01235442","phase":"PHASE3","title":"Evaluate Efficacy, and Safety of Topical Therapy and Etanercept in Subjects With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-09","conditions":"Psoriasis","enrollment":592},{"nctId":"NCT01323673","phase":"PHASE4","title":"Ethanol-Free Clobetasol Propionate Foam 0.05% (Olux-E Foam) vs Vehicle Foam in the Treatment of Chronic Hand Dermatitis.","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2010-11-15","conditions":"Dermatitis, Chronic","enrollment":125},{"nctId":"NCT00842153","phase":"PHASE4","title":"Evaluation of the Efficacy and Tolerability of Clobetasol Propionate Foam Compared to Vehicle Foam","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2007-11","conditions":"Psoriasis","enrollment":58},{"nctId":"NCT02973776","phase":"PHASE1","title":"Vasoconstriction Trial With LEO 90100 Aerosol Foam","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2016-12","conditions":"Psoriasis Vulgaris","enrollment":36},{"nctId":"NCT01745133","phase":"PHASE4","title":"Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis","status":"COMPLETED","sponsor":"Leon Kircik, M.D.","startDate":"2013-01","conditions":"Psoriasis","enrollment":63},{"nctId":"NCT00828464","phase":"PHASE4","title":"Study to Evaluate Safety, Efficacy and Tolerability of Clobetasol Propionate for Chronic Hand Dermatitis","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2008-10","conditions":"Hand Dermatosis","enrollment":30},{"nctId":"NCT00852761","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Tolerability of Topical Therapies for the Condition of Plaque-Type Psoriasis","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2009-03","conditions":"Plaque-Type Psoriasis","enrollment":34},{"nctId":"NCT01111981","phase":"PHASE4","title":"Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in Alopecia","status":"UNKNOWN","sponsor":"Callender Center for Clinical Research","startDate":"2009-10","conditions":"Alopecia","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":19,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Olux-E"],"phase":"marketed","status":"active","brandName":"Clobetasol propionate foam","genericName":"Clobetasol propionate foam","companyName":"Stiefel, a GSK Company","companyId":"stiefel-a-gsk-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Clobetasol propionate is a potent topical corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors. Used for Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (scalp and body), Psoriasis, Lichen planus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}